218 related articles for article (PubMed ID: 30206777)
1. A case of gastric cancer with delayed onset of tumor reduction effect by nivolumab therapy.
Satoyoshi R; Muto O; Masuda A; Kotanagi K; Kichiraku T; Kudoh K; Sawada T; Miyazawa H; Kotanagi H
Clin J Gastroenterol; 2019 Feb; 12(1):15-19. PubMed ID: 30206777
[TBL] [Abstract][Full Text] [Related]
2. Paraneoplastic dermatomyositis appearing after nivolumab therapy for gastric cancer: a case report.
Shibata C; Kato J; Toda N; Imai M; Fukumura Y; Arai J; Kurokawa K; Kondo M; Takagi K; Kojima K; Ohki T; Seki M; Yoshida M; Suzuki A; Tagawa K
J Med Case Rep; 2019 Jun; 13(1):168. PubMed ID: 31153385
[TBL] [Abstract][Full Text] [Related]
3. [Localized MSI/dMMR gastric cancer patients, perioperative immunotherapy instead of chemotherapy: The GERCOR NEONIPIGA phase II study is opened to recruitment].
Cohen R; Pudlarz T; Garcia-Larnicol ML; Vernerey D; Dray X; Clavel L; Jary M; Piessen G; Zaanan A; Aparicio T; Louvet C; Tournigand C; Chibaudel B; Tougeron D; Guimbaud R; Benouna J; Adenis A; Sokol H; Borg C; Duval A; Svrcek M; André T
Bull Cancer; 2020 Apr; 107(4):438-446. PubMed ID: 32057467
[TBL] [Abstract][Full Text] [Related]
4. [A Case of Unresectable Advanced Gastric Neuroendocrine Cell Carcinoma Treated with Nivolumab].
Yoshioka R; Nagase H; Noguchi K; Hamabe A; Hirota M; Oshima K; Tanida T; Ogino T; Tomimaru Y; Kawase T; Noura S; Imamura H; Iwasawa T; Akagi K; Ando H; Tamura H; Adachi S; Dono K
Gan To Kagaku Ryoho; 2018 Oct; 45(10):1530-1532. PubMed ID: 30382068
[TBL] [Abstract][Full Text] [Related]
5. Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone.
Afzal MZ; Mabaera R; Shirai K
J Immunother Cancer; 2018 Feb; 6(1):13. PubMed ID: 29433557
[TBL] [Abstract][Full Text] [Related]
6. [Experience with Nivolumab in the Treatment of Metastatic Gastric Cancer].
Takao C; Matsuhashi N; Murase Y; Yasufuku I; Tanahashi T; Yamaguchi K; Matsui S; Imai H; Tanaka Y; Takahashi T; Yoshida K
Gan To Kagaku Ryoho; 2018 Oct; 45(10):1546-1548. PubMed ID: 30382073
[TBL] [Abstract][Full Text] [Related]
7. Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer.
Sasaki A; Nakamura Y; Mishima S; Kawazoe A; Kuboki Y; Bando H; Kojima T; Doi T; Ohtsu A; Yoshino T; Kuwata T; Akimoto T; Shitara K
Gastric Cancer; 2019 Jul; 22(4):793-802. PubMed ID: 30627987
[TBL] [Abstract][Full Text] [Related]
8. [A Case of Gastric Cancer with Continued Progression-Free Survival Even after Total Gastrectomy and Nivolumab Therapy].
Fujii H; Choda Y; Kubota T; Ishida M; Sato D; Sumitani D; Yoshimitsu M; Nakano K; Harano M; Matsukawa H; Idani H; Shiozaki S; Okajima M
Gan To Kagaku Ryoho; 2019 Dec; 46(13):2318-2320. PubMed ID: 32156917
[TBL] [Abstract][Full Text] [Related]
9. A case of small bowel adenocarcinoma wherein nivolumab conferred temporary benefit in disease control.
Iijima K; Oozeki M; Ikeda K; Honda H; Ishibashi H; Yamaoka M; Fujieda S; Saitoh H; Goto M; Araki M; Amagai K
Clin J Gastroenterol; 2020 Jun; 13(3):372-376. PubMed ID: 31701367
[TBL] [Abstract][Full Text] [Related]
10. Tumor pseudoprogression during nivolumab immunotherapy for lung cancer.
Mayoral M; Castañer E; Gallardo X; Andreu M; Dalmau E; Garcia Y
Radiologia (Engl Ed); 2019; 61(6):498-505. PubMed ID: 31300214
[TBL] [Abstract][Full Text] [Related]
11. [Hyperprogressive Disease during Treatment with Nivolumab for Recurrence of Gastric Cancer].
Takeoka T; Okada K; Matsuno H; Konishi K; Ota H; Yokoyama S; Fukunaga M; Kobayashi K
Gan To Kagaku Ryoho; 2020 Jan; 47(1):165-167. PubMed ID: 32381893
[TBL] [Abstract][Full Text] [Related]
12. [A case report; 5'-DFUR reduced gastric cancer with multiple liver metastasis].
Kurimoto N; Yasuzawa Y; Itoh N; Tamura T; Yoshimoto I
Gan To Kagaku Ryoho; 1992 Jul; 19(7):1067-70. PubMed ID: 1385690
[TBL] [Abstract][Full Text] [Related]
13. Diffuse alveolar hemorrhage with pseudoprogression during nivolumab therapy in a patient with malignant melanoma.
Ikeda T; Yamaguchi H; Dotsu Y; Taniguchi H; Gyoutoku H; Senju H; Sakamoto N; Iwanaga S; Kuwatsuka Y; Fukuda M; Mukae H
Thorac Cancer; 2018 Nov; 9(11):1522-1524. PubMed ID: 30253076
[TBL] [Abstract][Full Text] [Related]
14. Radiologic Pseudoprogression during Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
Katz SI; Hammer M; Bagley SJ; Aggarwal C; Bauml JM; Thompson JC; Nachiappan AC; Simone CB; Langer CJ
J Thorac Oncol; 2018 Jul; 13(7):978-986. PubMed ID: 29738824
[TBL] [Abstract][Full Text] [Related]
15. [Brain Metastasis Arising from Gastric Cancer during Long-Term Treatment Using Nivolumab].
Namikawa T; Marui A; Yokota K; Kawanishi Y; Munekage M; Uemura S; Maeda H; Kitagawa H; Nagata Y; Kobayashi M; Hanazaki K
Gan To Kagaku Ryoho; 2022 Dec; 49(13):1544-1546. PubMed ID: 36733129
[TBL] [Abstract][Full Text] [Related]
16. Hyperprogressive disease in patients with non-small cell lung cancer treated with nivolumab: A case series.
Kanazu M; Edahiro R; Krebe H; Nishida K; Ishijima M; Uenami T; Akazawa Y; Yano Y; Yamaguchi T; Mori M
Thorac Cancer; 2018 Dec; 9(12):1782-1787. PubMed ID: 30328672
[TBL] [Abstract][Full Text] [Related]
17. Complete pathologic response after laparoscopic hepatectomy following treatment with nivolumab and ipilimumab for anticancer drug-resistant MSI-high colon cancer liver metastasis consisting of poorly differentiated adenocarcinoma with squamous differentiation: A case report.
Kato M; Sawayama H; Komohara Y; Hisano Y; Nakamura H; Ohuchi M; Ogawa K; Miyamoto Y; Yoshida N; Baba H
Clin J Gastroenterol; 2024 Feb; 17(1):57-64. PubMed ID: 37874527
[TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy of nivolumab is associated with tertiary lymphoid structures in surgically resected primary tumors of recurrent gastric cancer.
Mori T; Tanaka H; Deguchi S; Yamakoshi Y; Miki Y; Yoshii M; Tamura T; Toyokawa T; Lee S; Muguruma K; Ohira M
PLoS One; 2022; 17(1):e0262455. PubMed ID: 34995329
[TBL] [Abstract][Full Text] [Related]
19. [A case of metastatic gastric cancer showing long-term control with nivolumab after pseudoprogression].
Okamoto T; Ueda S
Nihon Shokakibyo Gakkai Zasshi; 2021; 118(6):549-554. PubMed ID: 34108354
[TBL] [Abstract][Full Text] [Related]
20. Dramatic response to nivolumab after local radiotherapy in pulmonary pleomorphic carcinoma with rapid progressive post-surgical recurrence.
Yaguchi D; Ichikawa M; Ito M; Okamoto S; Kimura H; Watanabe K
Thorac Cancer; 2019 May; 10(5):1263-1266. PubMed ID: 30860657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
